Aiming to validate the potential role of CXCR4 signaling on the sensitivity of B-ALL cells to Dex, we next treated B-ALL cell lines with different CXCR4 antagonists, i.e., AMD3100, AMD3465, WZ811 or MSK122, in combination with Dex (Supplementary Fig. 20g, h). The gene discussed is CXCR4; the disease is acute lymphoblastic leukemia.